SGLT2 inhibitor effects on artery stiffness, vessel lining thickness, and heart muscle after a heart attack
The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness , Left Atrial and Left Ventricular Deformation After Acute Myocardial Infarction
This project will see if SGLT2 inhibitors given after a heart attack improve blood vessel stiffness, the vessel's protective lining, and heart muscle function for people with type 2 diabetes or reduced heart pumping.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University of Athens Academic / other |
| Locations | 1 site (Athens, Rimini1/Haidari) |
| Trial ID | NCT07469943 on ClinicalTrials.gov |
What this trial studies
This observational study will follow people after ST-segment elevation myocardial infarction who have type 2 diabetes or a left ventricular ejection fraction below 40% to compare vascular and cardiac measures between those treated with SGLT2 inhibitors and those not treated. Investigators will record measurements of arterial stiffness, endothelial glycocalyx thickness, and myocardial deformation at baseline and during follow-up to track changes after the acute event. Key exclusions include significant chronic kidney disease (eGFR <60 ml/min/1.73 m²), active malignancy, autoimmune/autoinflammatory disorders, severe hepatic impairment, and pregnancy or breastfeeding. All study visits and measurements will be conducted at Attikon University Hospital in Athens as part of routine research follow-up.
Who should consider this trial
Good fit: Adults with ST-elevation myocardial infarction who have type 2 diabetes or an LVEF <40% and who meet safety criteria (eGFR ≥60, not pregnant, no active cancer or autoimmune disease) are ideal candidates.
Not a fit: Patients with eGFR <60 ml/min/1.73 m², active malignancy, autoimmune/autoinflammatory disease, severe hepatic impairment, or who are pregnant or breastfeeding are excluded and unlikely to receive benefit as studied.
Why it matters
Potential benefit: If positive, the findings could support using SGLT2 inhibitors to improve vascular function and limit adverse heart remodeling after myocardial infarction, potentially reducing heart failure and recurrent event risk.
How similar studies have performed: Large randomized trials have shown SGLT2 inhibitors reduce heart failure hospitalizations and cardiovascular death, but their specific effects on arterial stiffness, endothelial glycocalyx, and myocardial deformation after acute STEMI remain limited and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * STEMI participants with type 2 diabetes or LVEF\<40% Exclusion Criteria: 1. Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m² 2. Active malignancy 3. Autoimmune or autoinflammatory disorders 4. Severe hepatic impairment 5. Pregnancy or breastfeeding
Where this trial is running
Athens, Rimini1/Haidari
- Attikon University Hospital, 2nd Department of Cardiology, National and Kapodistrina University of Athens — Athens, Rimini1/Haidari, Greece (Recruiting)
Study contacts
- Study coordinator: Ignatios Ikonomidis, MD;PhD
- Email: ignoik@gmail.com
- Phone: 0030 6944805732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.